Marshmallow root is the mucilage-rich root of Althaea officinalis L., a botanical herbal substance studied in humans mainly for dry cough, irritated throat, mild gastrointestinal discomfort, topical skin conditions, and local oral mucosal symptoms. (EMA)
Marshmallow root has its clearest human evidence in Respiratory and Lung Health, especially studies of aqueous root extract syrups and lozenges for dry cough and throat irritation. (Research) The evidence for ordinary marshmallow root powder capsules is less direct because many human studies used extracts, syrups, lozenges, topical products, or local oral preparations rather than plain powder. (EMA) Overall evidence is best described as Limited / Mixed because the available human literature is formulation-specific and includes traditional-use assessments, observational studies, and small clinical trials rather than a large body of standardized randomized trials. (EMA)
Ingredient Identity
- Official name(s): Althaea officinalis L., radix; Althaeae radix; marshmallow root. (EMA)
- Synonyms: Althea root, marsh mallow root, marshmallow root. (FDA)
- Classification: Botanical herbal substance from the root of Althaea officinalis L. (EMA)
- CAS number: Not applicable to the whole botanical root as a single defined chemical substance.
- Endogenous vs exogenous: Exogenous botanical material; it is a plant-derived root preparation, not a compound produced by the human body. (EMA)
Ingredient Snapshot
- Classification: Marshmallow root is a botanical herbal substance from Althaea officinalis L., radix. (EMA)
- Endogenous vs exogenous status: It is an exogenous plant root preparation rather than an endogenous human metabolite. (EMA)
- Primary human research domains: Human evidence and authority-reviewed use focus mainly on Respiratory and Lung Health, Digestive and Gastrointestinal Health, Beauty and Skin Health, Oral Health, and Drug-Related Recovery contexts. (EMA)
- Common study formats: The evidence includes non-interventional surveys, EMA-reviewed observational studies, small randomized or controlled trials, topical clinical trials, and traditional-use assessments. (Research) (EMA)
- Pharmacokinetic characterization status: Human pharmacokinetic measures such as time to peak concentration, systemic bioavailability, and half-life are poorly characterized in the available clinical literature. (Research)
- Regulatory context, U.S.: The U.S. Food and Drug Administration, abbreviated FDA, lists althea root as a food-related substance used as a flavoring agent or adjuvant, which is not the same as approval for disease treatment. (FDA)
- Regulatory context, EU: The European Medicines Agency, abbreviated EMA, lists Althaeae radix as a herbal medicine and provides a finalized European Union herbal monograph for specified traditional-use preparations. (EMA)
- Evidence maturity: Overall evidence is Limited / Mixed, with the strongest human signal in formulation-specific respiratory use rather than broad supplement-style powder use. (EMA)
Introduction
Marshmallow root is the root of Althaea officinalis L., used in herbal preparations such as comminuted root macerates, aqueous liquid extracts, syrup macerates, dry extracts, and ethanol liquid extracts. (EMA) EMA treats these as distinct preparations, which means marshmallow root powder, aqueous extract, syrup, dry extract, and ethanol extract should not be assumed equivalent without formulation details. (EMA)
People often look up marshmallow root because of its traditional use for dry cough, irritated throat, and mild gastrointestinal discomfort, and because human studies have evaluated extract syrups, lozenges, drops, topical preparations, and local oral-use products. (Research) (EMA) The evidence has attracted interest because mucilage-rich preparations may act locally on irritated mucous membranes, but clinical confidence remains limited by formulation differences and by reliance on traditional-use or observational evidence. (Research) (EMA)
This article is informational only, describes marshmallow root as a botanical substance studied in human research, and does not provide medical or dosing advice.
Quick Summary
- Marshmallow root is the root of Althaea officinalis L., and research interpretation depends on whether the product is a powder, macerate, syrup, dry extract, liquid extract, lozenge, or topical preparation. (EMA)
- Human evidence is most developed for Respiratory and Lung Health, especially dry cough and irritated throat studies using aqueous root extract syrup or lozenges. (Research)
- Evidence for plain marshmallow root powder capsules is indirect because many studies used extract-based, syrup-based, topical, or local oral-use formulations. (EMA)
- EMA classifies specified marshmallow root preparations as traditional herbal medicinal products for oral or pharyngeal irritation with dry cough and for mild gastrointestinal discomfort. (EMA)
- Topical human studies have examined Althaea officinalis preparations in Beauty and Skin Health, but those findings do not establish effects for swallowed root powder. (Research)
- Human pharmacokinetic data are limited, so claims about systemic absorption, half-life, or blood-level effects should be made cautiously. (Research)
- FDA lists althea root as a food-related flavoring agent or adjuvant, while EMA provides a traditional herbal medicine monograph for specified root preparations. (FDA) (EMA)
Human Research Findings by Condition
Respiratory and Lung Health
Human research on Respiratory and Lung Health has mainly examined dry cough and throat irritation using aqueous marshmallow root extract syrup, lozenges, and EMA-reviewed traditional-use preparations. (Research) The evidence is suggestive but limited because key studies include non-interventional surveys, pediatric observational studies, and traditional-use assessments rather than multiple large randomized controlled trials. (EMA)
Key human study
Dose studied: Aqueous marshmallow root extract syrup and lozenges containing the studied extract preparation
Population: 822 pharmacy consumers with irritative dry cough
Duration: 7 days
Two prospective non-interventional surveys evaluated marshmallow root extract syrup and lozenges for irritative dry cough. Participants reported improvement in cough and throat irritation symptoms, and many users reported perceived onset within 10 minutes; however, the study was observational and based on user-reported outcomes. (Research)
Result: Observational human studies reported an association
Evidence strength: Observational
Study source: (Research)
Additional human study
Dose studied: Marshmallow syrup with water extract, drug-extract ratio 1:19.5–23.5
Population: 313 children with dry irritating cough and mucous membrane irritation
Duration: Average 3 days
EMA summarized a post-marketing surveillance study in children using marshmallow syrup for dry irritating cough. The report described physician and patient tolerability observations, but EMA noted the absence of objective measurements and treated the evidence as limited. (EMA)
Result: Human clinical studies reported mixed findings
Evidence strength: Limited
Study source: (EMA)
Drug-Related Recovery
Human research relevant to Drug-Related Recovery includes a small trial in cough associated with angiotensin-converting enzyme inhibitor medicines, often abbreviated ACE inhibitors. (Research) This evidence should be interpreted separately from ordinary dry cough studies because the cough was medication-associated and the tested drops were not fully characterized like the EMA monograph preparations. (EMA)
Key human study
Dose studied: 40 mg Althaea officinalis drops; 20 drops three times daily
Population: Adults with ACE-inhibitor-associated cough
Duration: 4 weeks
Rouhi and Ganji studied Althaea officinalis drops in adults with ACE-inhibitor-associated cough. The trial reported a reduction in cough score in the Althaea group, while spirometry parameters did not show significant differences; because formulation details are limited, the finding should not be generalized to all root powders or extracts. (Research)
Result: Randomized human trial reported a statistically significant improvement
Evidence strength: Limited
Study source: (Research)
Additional human study
Dose studied: Same ACE-inhibitor cough trial summarized in EMA evidence review
Population: Adults with ACE-inhibitor-associated cough
Duration: 4 weeks
EMA reviewed the Rouhi and Ganji study as part of the clinical evidence base for marshmallow root. EMA still concluded that available evidence did not support well-established medicinal use, which limits how strongly this study can be interpreted. (EMA)
Result: Human clinical studies reported mixed findings
Evidence strength: Limited
Study source: (EMA)
Digestive and Gastrointestinal Health
Digestive and Gastrointestinal Health evidence for marshmallow root is mainly traditional-use evidence rather than modern condition-specific clinical trial evidence. (EMA) EMA includes mild gastrointestinal discomfort as a traditional-use indication for specified root preparations, but the available evidence does not support disease-specific claims for ulcers, reflux, inflammatory bowel disease, or irritable bowel syndrome. (EMA)
Key human study
Dose studied: 2–5 g comminuted root in 150 mL water, 3 times daily; maximum 15 g/day
Population: Adolescents, adults, and elderly people in traditional-use context
Duration: Traditional-use monograph context rather than a single clinical trial duration
EMA lists marshmallow root preparations for mild gastrointestinal discomfort based on traditional use. This is an authority-reviewed traditional-use classification, not a randomized clinical trial showing treatment of a specific gastrointestinal disease. (EMA)
Result: Human evidence remains limited or inconclusive
Evidence strength: Limited
Study source: (EMA)
Beauty and Skin Health
Human research in Beauty and Skin Health has studied topical Althaea officinalis preparations, especially eczema-related outcomes. (Research) These findings are route-specific because the studied preparations were topical extracts, not swallowed marshmallow root powder, tea, syrup, or capsules. (Research)
Key human study
Dose studied: 10% topical liposomal Althaea officinalis flower extract
Population: 40 patients with atopic eczema
Duration: 4 weeks
A double-blind randomized controlled trial compared a topical liposomal Althaea officinalis flower extract formulation with comparator treatment areas in atopic eczema. The study reported improvement in SCORAD, a standardized atopic dermatitis severity score, but the plant part and topical route differ from oral marshmallow root products. (Research)
Result: Randomized human trial reported a statistically significant improvement
Evidence strength: Limited
Study source: (Research)
Additional human study
Dose studied: 1% topical Althaea officinalis ointment
Population: Children with atopic dermatitis
Duration: Pilot active-controlled study
A pilot double-blind active-controlled clinical trial compared Althaea officinalis 1% ointment with hydrocortisone 1% in children with atopic dermatitis. PubMed identifies the study as a topical pediatric trial, so it can support topical-study context but not oral root supplement claims. (Research)
Result: Human clinical study reported a modest improvement
Evidence strength: Emerging
Study source: (Research)
Oral Health
Human research in Oral Health includes local-use research on hydroalcoholic Althaea officinalis root extract for chemotherapy-induced stomatitis. (Research) This evidence concerns local oral mucosal symptoms and does not establish effects for swallowed marshmallow root powder supplements. (Research)
Key human study
Dose studied: Hydroalcoholic Althaea officinalis root extract preparation used locally in the mouth
Population: Patients with chemotherapy-induced stomatitis
Duration: Clinical trial context described by the study
A randomized clinical trial studied hydroalcoholic Althaea officinalis root extract in chemotherapy-induced stomatitis. Because the context was local oral mucosal care in a specific patient group, the finding should be interpreted as local-use evidence rather than evidence for general oral supplementation. (Research)
Result: Randomized human trial reported a statistically significant improvement
Evidence strength: Limited
Study source: (Research)
Additional human study
Dose studied: Hydroalcoholic extract use in stomatitis grades 1–3
Population: Cancer patients with chemotherapy-induced stomatitis
Duration: Trial context described in the source PDF
The full PDF identifies the study as a triple-blind clinical trial in cancer patients with chemotherapy-induced stomatitis. This supports the local-use study design, but it does not broaden the evidence to unrelated oral conditions or oral supplement formats. (Research)
Result: Human clinical study reported a modest improvement
Evidence strength: Limited
Study source: (Research)
Dosage & Study Snapshot (Research Context)
Human marshmallow root exposure evidence is mainly formulation-based, not built from modern pharmacokinetic dose-ranging studies. (EMA) The most important distinction is between comminuted root or powder-like plant material, aqueous extracts, syrup macerates, dry extracts, and liquid extracts; DER, or drug-extract ratio, describes the relationship between the amount of starting plant material and the finished extract and should not be treated as the same thing as powder weight. (EMA)
0.21–1.16 g/day herbal-substance equivalent, syrup macerate:
EMA lists a syrup macerate exposure corresponding to 0.1–0.29 g herbal-substance equivalent per 5 mL, up to 4 times daily, for children aged 3–5 years in the cough and throat-irritation traditional-use context. (EMA) This is the lowest documented exposure band in the reviewed dose sources. The value is expressed as herbal-substance equivalent, not as the direct weight of finished extract or root powder. This band is useful for interpreting syrup-style preparations, but it should not be applied directly to capsule products labeled only as marshmallow root powder.
Result: Inconclusive
Evidence strength: Limited
Notes / limitations: This is a monograph exposure band, not a standalone randomized efficacy trial.
1.5–3.0 g/day comminuted root macerate:
EMA lists 0.5–1.0 g comminuted root in 150 mL water, 3 times daily, for children aged 3–5 years in the traditional-use cough and throat-irritation context. (EMA) Comminuted root means cut or powdered plant material prepared with water. This is closer to powder-like plant material than syrup or dry extract, but it is still a hydrated preparation rather than a dry capsule. The evidence context is traditional-use dosing, not modern dose-response pharmacology.
Result: Inconclusive
Evidence strength: Limited
Notes / limitations: Water preparation may affect mucilage availability compared with dry powder capsules.
1.5–4.5 g/day comminuted root macerate:
EMA lists 0.5–1.5 g comminuted root in 150 mL water, 3 times daily, for children aged 6–11 years in the cough and throat-irritation traditional-use context. (EMA) This band remains a water-prepared comminuted-root preparation rather than a standardized extract. The age group and traditional-use context differ from adult supplement-market use. This dose band helps describe historical and regulatory use patterns but does not establish an optimal dose.
Result: Inconclusive
Evidence strength: Limited
Notes / limitations: Pediatric traditional-use exposure should not be generalized to adult capsule use.
Up to 15 g/day comminuted root macerate:
EMA lists 0.5–3 g comminuted root in 150 mL water several times daily, with a maximum daily dose of 15 g/day, for adolescents, adults, and elderly people in the oral or pharyngeal irritation and dry cough context. (EMA) This is the main adult/adolescent comminuted-root range in the EMA monograph. The preparation is a water macerate, which matters because mucilage-containing roots are often used in hydrated forms. This band should not be converted automatically into an extract dose because extracts differ by solvent, concentration, and DER.
Result: Inconclusive
Evidence strength: Limited
Notes / limitations: The monograph range describes traditional-use preparation, not proven dose-response efficacy.
6–15 g/day comminuted root macerate for mild gastrointestinal discomfort:
EMA lists 2–5 g comminuted root in 150 mL water, 3 times daily, with a maximum daily dose of 15 g/day, for adolescents, adults, and elderly people in the mild gastrointestinal discomfort traditional-use context. (EMA) This band is tied to Digestive and Gastrointestinal Health rather than cough. It is not based on a reviewed randomized trial for a named gastrointestinal disease. It is best interpreted as an authority-reviewed traditional-use preparation band.
Result: Inconclusive
Evidence strength: Limited
Notes / limitations: This dose band does not support disease-treatment claims for ulcers, reflux, or inflammatory bowel disease.
7.6 g/day aqueous liquid extract, DER 1:19.5–23.5:
EMA lists 1.9 g liquid extract 4 times daily for children aged 3–5 years, using a liquid extract with DER 1:19.5–23.5 and water as the extraction solvent. (EMA) A DER of 1:19.5–23.5 describes the relationship between starting root material and finished liquid extract, not a simple powder-equivalent dose. This band is relevant to aqueous liquid preparations, not plain powder. It should be compared only with products that clearly disclose similar extract specifications.
Result: Inconclusive
Evidence strength: Limited
Notes / limitations: The formulation is an aqueous liquid extract, not root powder.
11.5 g/day aqueous liquid extract, DER 1:19.5–23.5:
EMA lists 2.3 g liquid extract 5 times daily for children aged 6–11 years, using the same water-extracted DER 1:19.5–23.5 preparation type. (EMA) This exposure is formulation-specific and pediatric. It is relevant to syrup-style or liquid extract products, not generic root powder products. The dose band illustrates why marshmallow extract labels need extraction-ratio and solvent context.
Result: Inconclusive
Evidence strength: Limited
Notes / limitations: Pediatric liquid extract exposure should not be treated as an adult supplement dose.
13.8–27.6 g/day aqueous liquid extract, DER 1:19.5–23.5:
EMA lists 4.6 g liquid extract 3–6 times daily for adolescents, adults, and elderly people, using a water-extracted DER 1:19.5–23.5 preparation. (EMA) This is a higher liquid-extract exposure band for cough and throat-irritation traditional use. It differs from dry extract because it is a finished liquid preparation rather than a dried concentrated material. It also differs from comminuted root because extraction solvent and ratio affect interpretation.
Result: Inconclusive
Evidence strength: Limited
Notes / limitations: The gram value refers to liquid extract mass, not grams of dried root powder.
1.5–3 g/day herbal-substance equivalent as dry extract, DER 3–9:1:
EMA lists 0.5–1 g herbal-substance equivalent, 3 times daily, for children aged 3–5 years, using a dry extract with DER 3–9:1 and water as the extraction solvent. (EMA) A dry extract can differ from raw plant powder because extraction and concentration change the finished material. The monograph expresses this dose as herbal-substance equivalent, which helps separate starting root equivalent from finished extract weight. This distinction is important when comparing research-style extracts with commercial supplement labels.
Result: Inconclusive
Evidence strength: Limited
Notes / limitations: The source gives herbal-substance equivalent, not a universal dry-extract capsule dose.
Up to 15 g/day herbal-substance equivalent as dry extract, DER 3–9:1:
EMA lists 0.5–3 g herbal-substance equivalent several times daily, with a maximum daily dose of 15 g/day, for adolescents, adults, and elderly people using a water-extracted dry extract DER 3–9:1. (EMA) This band belongs to the same preparation family as the lower pediatric dry-extract band. It should be interpreted as an extract-equivalent exposure rather than a direct powder-weight instruction. The evidence remains traditional-use based rather than pharmacokinetic dose optimization.
Result: Inconclusive
Evidence strength: Limited
Notes / limitations: Extract standardization details are essential for interpreting this band.
2.5–10 mL syrup, 4–6 times daily:
EMA summarizes a post-marketing pediatric surveillance study using marshmallow syrup with water extract, DER 1:19.5–23.5, at 2.5–10 mL 4–6 times daily. (EMA) The population included children with dry irritating cough and mucous membrane irritation. The study context supports real-world use and tolerability observations, but it lacked objective outcome measures. This exposure should be interpreted as syrup-specific and pediatric.
Result: Observational association
Evidence strength: Observational
Notes / limitations: The study was post-marketing surveillance, not a blinded efficacy trial.
1–5 mL syrup, 1–6 times daily:
EMA summarizes a retrospective pediatric study using marshmallow syrup with water extract, DER 1:19.5–23.5, at 1–5 mL 1–6 times daily. (EMA) The study involved children with dry cough and pharyngeal irritation. Reported outcomes were observational and physician-rated rather than objective clinical endpoints. The study is useful for formulation context but not for proving general efficacy.
Result: Observational association
Evidence strength: Observational
Notes / limitations: Retrospective design limits confidence.
40 mg drops, 20 drops three times daily:
Rouhi and Ganji studied 40 mg Althaea officinalis drops, given as 20 drops three times daily, in adults with ACE-inhibitor-associated cough. (Research) The trial reported improvement in cough score in the Althaea group, but the source does not fully characterize extract ratio, solvent, or powder-equivalent exposure. This makes the study relevant but difficult to compare with EMA monograph preparations or commercial supplement products. The dose belongs in a separate study-specific band rather than being merged with powder or extract ranges.
Result: Statistically significant improvement
Evidence strength: Limited
Notes / limitations: The exact formulation details are incomplete.
Key Takeaways from Human Research
- Human evidence is most concentrated in Respiratory and Lung Health, especially dry cough and irritated throat studies using aqueous extract syrup, lozenges, and traditional-use preparations. (Research) (EMA)
- Evidence for marshmallow root powder capsules is weaker than evidence for aqueous extract and syrup preparations because the studied preparations often differ from powder in solvent, concentration, and DER. (EMA)
- Digestive and Gastrointestinal Health use is supported mainly by EMA traditional-use classification rather than condition-specific randomized clinical trials. (EMA)
- Beauty and Skin Health studies involve topical extract preparations, so they do not establish effects for swallowed marshmallow root products. (Research) (Research)
- Oral Health evidence includes local-use research in chemotherapy-induced stomatitis, but this context is not the same as general oral supplementation. (Research)
- Overall evidence remains Limited / Mixed because many data sources are observational, traditional-use based, small, formulation-specific, or local-use rather than systemic supplement trials. (EMA)
Origin & Natural Occurrence
Marshmallow root comes from the root of Althaea officinalis L., and EMA identifies the medicinal herbal substance as Althaea officinalis L., radix. (EMA) The available evidence identifies marshmallow root as an exogenous botanical material rather than a substance produced by the human body. (EMA)
Marshmallow root preparations can be made as comminuted herbal substance, aqueous liquid extract, syrup macerate, aqueous dry extract, or ethanol liquid extract. (EMA) These preparations are not automatically interchangeable because starting root material, extraction solvent, water contact, and final concentration can differ. (EMA)
How It Behaves in the Body
Marshmallow root is mainly discussed as a local mucilage-containing botanical rather than as a well-characterized systemic compound. (Research) Mucilage means water-binding plant polysaccharides that can form a slippery, coating material when hydrated, which helps explain why water-based preparations appear prominently in respiratory and throat-irritation research. (Research)
Laboratory research using human epithelial cells found that aqueous marshmallow root extracts and isolated polysaccharides could form bioadhesive layers and influence epithelial-cell physiology in vitro. (Research) Bioadhesion means that a material can adhere to a biological surface, which is relevant to the idea of local contact with irritated mucous membranes. (Research)
Other experimental studies have examined marshmallow root extract in activated macrophage and endothelial-cell models, but these studies do not establish systemic clinical effects in humans. (Research) (Research) The best-supported interpretation is local demulcent plausibility, while systemic pharmacokinetics and systemic health outcomes remain poorly characterized. (Review)
Absorption & Delivery Formats
Oral immediate-release: Oral immediate-release formats in the available evidence include comminuted root macerates, aqueous liquid extracts, syrup macerates, dry extracts, and drops. (EMA) These formats should be interpreted separately because DER, extraction solvent, and water preparation can materially affect exposure. (EMA)
Oral extended-release: The reviewed evidence does not include human studies of extended-release marshmallow root products. (EMA) Claims about extended-release marshmallow root pharmacokinetics should therefore be avoided unless product-specific evidence is available.
Sublingual or lozenge-like local delivery: Lozenges were included in the Fink non-interventional surveys, where users evaluated marshmallow root extract lozenges for irritative dry cough and throat irritation. (Research) This format is best understood as local oral or pharyngeal exposure rather than proof of systemic absorption. (Research)
Transdermal or topical: Topical Althaea officinalis preparations have been studied in atopic eczema and pediatric atopic dermatitis. (Research) (Research) These are skin-directed applications rather than systemic transdermal pharmacokinetic studies.
Injectable / IV: The available evidence does not include injectable or intravenous marshmallow root preparations. (EMA) Injectable or IV claims should not be made without verified clinical evidence.
Quick Facts at a Glance
Onset reported: In the Fink surveys, many users of marshmallow root extract syrup or lozenges reported perceived symptom relief within 10 minutes. (Research) This is a user-reported onset in a non-interventional study, not a controlled pharmacodynamic onset measurement. (Research)
Time to peak, or Tmax: Human Tmax, meaning time to peak blood concentration, is not characterized in the available marshmallow root clinical sources. (Research) This gap reflects that marshmallow root has been studied mainly as a local mucilage preparation rather than a systemically absorbed drug-like compound. (Research)
Half-life, or t½: Human half-life is not established in the available evidence. (EMA) Because the evidence emphasizes local preparations and traditional use, half-life should not be inferred from unrelated botanical compounds. (EMA)
Typical duration: The Fink surveys followed users for 7 days, while the ACE-inhibitor cough trial lasted 4 weeks. (Research) (Research) EMA-reviewed pediatric cough studies included short-use observational contexts, including an average of 3 days in one post-marketing surveillance study. (EMA)
Absorption routes studied: The available evidence includes oral macerates, syrups, lozenges, drops, topical skin preparations, and local oral-use preparations. (EMA) These routes do not provide a complete systemic absorption profile for marshmallow root. (Research)
Formulation differences: EMA distinguishes comminuted root, aqueous liquid extract, syrup macerate, aqueous dry extract, and ethanol liquid extract. (EMA) A study using aqueous syrup or lozenges should not be treated as direct evidence for an unrelated dry root powder capsule. (Research)
Variability drivers: Interpretation depends on plant part, preparation method, extraction solvent, DER, and local contact time. (EMA) These variables affect whether a product resembles a studied aqueous extract, syrup, macerate, dry extract, or topical formulation. (EMA)
Tolerance / adaptation: Human tolerance or adaptation studies for marshmallow root were not identified in the reviewed evidence. (EMA) Therefore, claims that tolerance develops or does not develop should be avoided.
Evidence strength snapshot: Evidence is strongest for formulation-specific respiratory use, but it remains limited by observational designs, traditional-use framing, and preparation differences. (Research) (EMA) Evidence for generic powder capsules, systemic effects, and pharmacokinetics is weak. (Research)
Safety, Interactions & Regulation
Human tolerability evidence for marshmallow root is limited but includes syrup and lozenge surveys and EMA-reviewed pediatric syrup data. (Research) In the Fink surveys of syrup and lozenges, three minor adverse events were reported for syrup, and the study design was non-interventional. (Research)
EMA’s assessment report summarizes pediatric syrup studies, including a post-marketing surveillance study and a retrospective study, but these designs provide lower-strength safety evidence than controlled safety trials. (EMA) EMA’s monograph includes age-related restrictions and preparation-specific instructions, including that use in children under 3 years is not recommended for the cough and throat-irritation indication and that gastrointestinal-use preparations are not recommended in children under 12 years. (EMA)
EMA states that use during pregnancy and lactation is not recommended because adequate data are lacking. (EMA) The reviewed sources do not establish clinically proven drug interactions, but mucilage-containing preparations are best interpreted cautiously because their local coating properties are formulation-dependent. (Research)
In the United States, FDA lists althea root, marsh mallow root, and Althaea officinalis as a food-related substance with the technical effect “flavoring agent or adjuvant.” (FDA) FDA’s food-substance listing does not constitute approval of marshmallow root for treating cough, gastrointestinal discomfort, eczema, stomatitis, or any disease. (FDA)
In the European Union context, EMA lists Althaeae radix as a herbal medicine and provides a finalized European Union herbal monograph. (EMA) EMA classifies the specified preparations as traditional herbal medicinal products for oral or pharyngeal irritation with dry cough and for mild gastrointestinal discomfort, based on long-standing use rather than sufficient evidence for well-established use. (EMA)
Evidence Overview
The overall human evidence for marshmallow root is Limited / Mixed, with the clearest evidence in Respiratory and Lung Health for dry cough and irritated throat using aqueous extract syrup, lozenges, or EMA-reviewed traditional-use preparations. (Research) (EMA) Confidence is not higher because the evidence includes non-interventional surveys, observational pediatric studies, traditional-use assessments, topical trials, and local oral-use studies rather than multiple large randomized controlled trials of one standardized root preparation. (EMA)
Dry cough and throat irritation are the most developed human research areas, but the best modern cough study in the reviewed evidence is a pair of prospective non-interventional surveys rather than a blinded randomized trial. (Research) EMA also reviewed pediatric syrup observations and an ACE-inhibitor cough trial, but it maintained a traditional-use rather than well-established-use framing. (EMA)
Evidence for Digestive and Gastrointestinal Health is weaker because it is supported mainly by EMA traditional-use classification for mild gastrointestinal discomfort. (EMA) The reviewed evidence does not provide condition-specific randomized human trials for ulcers, reflux, irritable bowel syndrome, inflammatory bowel disease, or other specific gastrointestinal diagnoses. (EMA)
Beauty and Skin Health evidence is separate because it comes from topical extract studies rather than oral root studies. (Research) Oral Health evidence is also separate because it includes local-use research for chemotherapy-induced stomatitis rather than swallowed supplement exposure. (Research)
The main interpretive challenge is formulation. EMA distinguishes comminuted root, aqueous liquid extract, syrup macerate, aqueous dry extract, and ethanol liquid extract, and these forms cannot be assumed equivalent to each other. (EMA) Future confidence would be strengthened by larger randomized controlled trials using clearly defined root preparations, transparent DER values, direct powder-versus-extract comparisons, objective symptom endpoints, and better human pharmacokinetic or local-retention data. (EMA)
Evidence Confidence Classification
Limited / Mixed is the overall human evidence classification for marshmallow root because human studies exist, but the evidence is limited by small study numbers, observational designs, formulation differences, traditional-use framing, and incomplete pharmacokinetic characterization. (Research) (EMA)
The strongest area is Respiratory and Lung Health, especially dry cough and throat irritation using aqueous extract syrup, lozenges, and traditional-use preparations. (Research) Evidence for Digestive and Gastrointestinal Health is weaker because it rests mainly on EMA traditional-use classification rather than modern clinical trials for specific gastrointestinal diseases. (EMA)
Mechanistic evidence supports local mucilage and bioadhesion plausibility, but mechanistic studies do not establish systemic human outcomes. (Research) The evidence base should therefore be interpreted as formulation-specific and locally oriented, not interchangeable across powder, extract, syrup, lozenge, topical, and local mouthwash-style preparations. (EMA)
Similar Ingredients & Comparators
Similar supplement-style ingredients:
- Slippery elm bark
- Licorice root
- Mullein leaf
- Ivy leaf extract
- Thyme extract
- Plantain leaf
- Hyssop
- Malva sylvestris
- Honey-based throat preparations
- Pectin-containing lozenges
Medical / pharma comparator categories:
- Demulcent throat preparations
- Antitussive medicines
- Expectorant medicines
- ACE-inhibitor cough management approaches
- Topical corticosteroids for eczema
- Oral mucositis supportive-care products
Combination Context
Marshmallow root extract + lozenge delivery format:
Marshmallow root extract lozenges were studied in non-interventional surveys for irritative dry cough and throat irritation. (Research) This format is relevant because lozenges provide local oral or throat contact, but the study does not prove that all lozenge or gummy products will perform the same way. (Research)
Marshmallow root extract + syrup delivery format:
Marshmallow root extract syrup was studied in the same survey program and appears in EMA-reviewed pediatric observational data. (Research) (EMA) Syrup evidence should be interpreted as formulation-specific because aqueous extract syrups are not equivalent to dry root powder capsules. (EMA)
Marshmallow root + topical vehicle:
Topical Althaea officinalis preparations have been studied in atopic eczema and pediatric atopic dermatitis research. (Research) (Research) These topical contexts are useful for Beauty and Skin Health evidence but should not be used to support claims about swallowed marshmallow root products.
FAQ
What is marshmallow root?
Marshmallow root is the root of Althaea officinalis L., recognized by EMA as Althaeae radix. (EMA) It is a botanical herbal substance, not a compound produced by the human body. (EMA) It is commonly discussed in relation to mucilage-rich preparations that may act locally on irritated mucous membranes. (Research)
What does human research study it for?
Human research studies marshmallow root mainly for Respiratory and Lung Health, especially dry cough and throat irritation. (Research) EMA-reviewed evidence also includes mild gastrointestinal discomfort and ACE-inhibitor-associated cough. (EMA) Other human evidence includes topical Beauty and Skin Health studies and local Oral Health research. (Research) (Research)
What are the best-supported uses?
The best-supported area is Respiratory and Lung Health for dry cough and throat irritation using aqueous extract syrup, lozenges, or EMA-reviewed traditional-use preparations. (Research) This evidence is still limited because major sources include non-interventional surveys and traditional-use assessments rather than multiple large randomized controlled trials. (EMA) Evidence should not be generalized automatically to plain root powder capsules. (EMA)
Where is evidence mixed or limited?
Evidence is mixed or limited for powder capsules, systemic effects, specific gastrointestinal diseases, and broad skin or oral health claims. (EMA) Digestive and Gastrointestinal Health use is supported mainly by EMA traditional-use classification rather than disease-specific randomized trials. (EMA) Topical skin studies and local oral studies are not interchangeable with swallowed supplement evidence. (Research) (Research)
How quickly does it act?
A non-interventional survey study reported that many users perceived improvement within 10 minutes after using marshmallow root extract syrup or lozenges. (Research) This is not the same as a controlled pharmacokinetic onset measurement. (Research) The available evidence does not establish a general onset time for root powder capsules. (EMA)
What affects absorption and variability?
Formulation affects interpretation because EMA distinguishes comminuted root, aqueous liquid extract, syrup macerate, aqueous dry extract, and ethanol liquid extract. (EMA) DER, extraction solvent, water contact, plant part, and route of use can affect whether a product resembles a studied preparation. (EMA) Human systemic absorption parameters are not well characterized. (Research)
Is tolerance reported?
Tolerance or adaptation is not established in the available human evidence. (EMA) The available studies focus on short-term symptom contexts, traditional use, topical outcomes, and local-use observations. (Research) Claims that tolerance develops or does not develop should therefore be avoided unless direct evidence is available.
Why do studies disagree?
Studies vary because marshmallow root products differ by formulation, including comminuted root, aqueous extract, syrup macerate, dry extract, ethanol extract, topical extract, and local oral-use extract. (EMA) Study designs also vary, including surveys, observational pediatric studies, small trials, topical trials, and traditional-use assessments. (Research) (EMA) These differences reduce confidence in broad claims about all marshmallow root products. (EMA)
What ingredients is it commonly combined with and why?
The reviewed marshmallow-root-specific evidence is stronger for delivery formats such as syrups and lozenges than for clearly proven multi-ingredient combinations. (Research) Syrup and lozenge formats are relevant because they can provide local oral or throat contact, but that does not prove equivalence for gummies, capsules, or unrelated combination products. (Research) Any combination claim should identify whether marshmallow root’s independent contribution was actually tested. (EMA)
What foods naturally contain this ingredient?
Marshmallow root is the root of Althaea officinalis L., not a normal endogenous human compound. (EMA) FDA lists althea root as a food-related substance used as a flavoring agent or adjuvant. (FDA) The reviewed evidence does not establish ordinary dietary intake levels from common foods. (FDA)
How is it regulated?
In the United States, FDA lists althea root, marsh mallow root, and Althaea officinalis as a food-related substance with the technical effect “flavoring agent or adjuvant.” (FDA) In the European Union context, EMA lists Althaeae radix as a herbal medicine with a finalized European Union herbal monograph. (EMA) EMA classifies specified preparations as traditional herbal medicinal products for oral or pharyngeal irritation with dry cough and mild gastrointestinal discomfort. (EMA)
Resources
EMA European Union herbal monograph on Althaea officinalis L., radix — European Medicines Agency — https://www.ema.europa.eu/en/documents/herbal-monograph/final-european-union-herbal-monograph-althaea-officinalis-l-radix_en.pdf
EMA assessment report on Althaea officinalis L., radix — European Medicines Agency — https://www.ema.europa.eu/en/documents/herbal-report/final-assessment-report-althaea-officinalis-l-radix_en.pdf
EMA herbal medicine page: Althaeae radix — European Medicines Agency — https://www.ema.europa.eu/en/medicines/herbal/althaeae-radix
EMA addendum assessment report on Althaea officinalis L., radix — European Medicines Agency — https://www.ema.europa.eu/en/documents/herbal-report/addendum-assessment-report-althaea-officinalis-l-radix_en.pdf
FDA Substances Added to Food: Althea Root — U.S. Food and Drug Administration — https://hfpappexternal.fda.gov/scripts/fdcc/index.cfm?id=ALTHEAROOT&set=FoodSubstances
Marshmallow Root Extract for the Treatment of Irritative Cough — PubMed — https://pubmed.ncbi.nlm.nih.gov/30064132/
Effect of Althaea officinalis on ACE-inhibitor cough — Pakistan Journal of Nutrition — https://pjnonline.org/pjn/article/view/478
Liposomal Althaea officinalis flower extract in atopic eczema — Beni-Suef University Journal of Basic and Applied Sciences — https://link.springer.com/article/10.1186/s40816-021-00306-z
Althaea officinalis 1% ointment in pediatric atopic dermatitis — PubMed — https://pubmed.ncbi.nlm.nih.gov/33034099/
Hydroalcoholic Althaea officinalis extract in chemotherapy-induced stomatitis — Journal of Nursing and Midwifery Sciences — https://journals.lww.com/nams/fulltext/2019/08010/effect_of_hydroalcoholic_extract_of_althaea.3.aspx
More from the Supplement Ingredients & Medical Ingredients Encyclopedia
